You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Mercurous Bromide For Enhanced Gamma Rays and Neutrons Detection Capabilities
SBC: BRIMROSE TECHNOLOGY CORP Topic: AF151009ABSTRACT: To ensure the United States remains safe from the threat of nuclear and radiological attacks requires advanced radiation detection with the ability to quickly and accurately detect illicit nuclear materials including dirty bombs and other dangerous radioisotopes. Existing nuclear radiation systems are still heavily based on technologies developed decades ago. These old technologies have ...
SBIR Phase I 2015 Department of DefenseAir Force -
Development of efficient and scalable bioreactor-based production of human Mesenchymal Stem Cell (hMSC) 3D aggregates using microparticles with thermo-reversible surfaces
SBC: ROOSTERBIO, INC. Topic: NHLBIDESCRIPTION provided by applicant Mesenchymal Stem Cells or MSC will be key components of future therapeutics engineered tissues and medical devices There are currently over clinical trials CT investigating MSC as therapies The CT have produced some promising results with MSC generally deemed safe and effective The promise of MSC has resulted in an increased demand for research ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimizing correction of the Huntington's disease mutation by trans-splicing
SBC: RETROTHERAPY, LLC Topic: 102DESCRIPTION provided by applicant Recent studies by my laboratory and collaborators and by others have demonstrated that RNA trans splicing can correct mutations in many different genes in a wide range of disease model systems including Huntingtonandapos s disease Trans splicing is one of a handful of techniques that can convert the expression of a dominant negative mutation into the normal p ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Avatar Assisted Therapy for Probationers and Parolees with Substance Use Disorders
SBC: COG ANALYTICS, LLC Topic: 102DESCRIPTION provided by applicant Substance use disorders SUDs continue to be one of the most serious public health problems in the US Studies have consistently documented a substantially higher prevalence of SUDs among individuals under criminal justice supervision At year end approximately million adults were under criminal justice supervision in the US of which million i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Continuing Care App for Probationers and Parolees with Substance Use Disorders
SBC: COG ANALYTICS, LLC Topic: NIMHDDESCRIPTION provided by applicant Substance use disorders SUDs continue to be one of the most serious public health problems in the US Studies have consistently documented a substantially higher prevalence of SUDs among individuals under criminal justice supervision At year end approximately million adults were on probation or parole in adults African American probationer ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Targeting endogenous sialidases for treatment of endotoxic shock
SBC: Oncoimmune Inc Topic: NIAIDDESCRIPTION provided by applicant Despite the advance of antibiotics sepsis remains a major challenge to human health as both survival and incidence of severe sepsis have been largely unchanged in the last two decades It is therefore important to develop new therapeutic approaches We have recently reported that bacterial sialidases may serve as therapeutic targets for polybacterial sepsis H ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis
SBC: REVERAGEN BIOPHARMA, INC. Topic: NIAMSDESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat rheumatoid arthritis RA Despite effectiveness many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of RA patients In addition juvenile arthritis patients suffer from th side effect of signi ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Detection of Minimal Residual Disease through Analysis of Genetic Alterations in the Circulation of Stage II Colorectal Cancer Patients
SBC: Personal Genome Diagnostics Inc. Topic: NCIDESCRIPTION provided by applicant With over million new cases and over deaths annually colorectal cancer CRC is the third most common cancer and the third highest cause of cancer death in the developed world CRC patients are classified into stage I through IV depending on the extent of their disease Approximately of CRC patients are diagnosed with localized stage II cancer ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A dual-polarized Doppler Radar system for fall detection in an indoor environment
SBC: MS Technologies Corporation Topic: NIADESCRIPTION provided by applicant Falls are a leading cause of injuries and deaths among older adults OAs and will be an increasing public health concern given projections of future increases in the number of OAs in the US Fall detection and or surveillance systems are needed to enhance an OAandapos s confidence and independence and to facilitate rapid post fall responses This project wil ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a mimetic multimodal peptide for the treatment of macular edema
SBC: Asclepix Therapeutics, Inc. Topic: NDESCRIPTION provided by applicant Macular edema ME is a common disease secondary to retinal vein occlusion and both Type I and Type Diabetes It is the leading cause of blindness in people between the ages of Lucentis and Eylea have been approved for the treatment of ME Although effective they do not increase the visual acuity for about half the patients suffering from ME We have ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health